US20130136733A1 - Stable Multi-Dose Compositions Comprising an Antibody and a Preservative - Google Patents

Stable Multi-Dose Compositions Comprising an Antibody and a Preservative Download PDF

Info

Publication number
US20130136733A1
US20130136733A1 US13/699,847 US201113699847A US2013136733A1 US 20130136733 A1 US20130136733 A1 US 20130136733A1 US 201113699847 A US201113699847 A US 201113699847A US 2013136733 A1 US2013136733 A1 US 2013136733A1
Authority
US
United States
Prior art keywords
composition
composition according
cresol
phenol
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/699,847
Other languages
English (en)
Inventor
Henrik Parshad
Dorthe Kot Engelund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to US13/699,847 priority Critical patent/US20130136733A1/en
Assigned to NOVO NORDISK A/S reassignment NOVO NORDISK A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ENGELUND, DORTE KOT, PARSHAD, HENRIK
Publication of US20130136733A1 publication Critical patent/US20130136733A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Definitions

  • the invention relates to stable, multi-dose liquid compositions containing proteins, in particular, but not exclusively stable antibodies, and to the use of said compositions in therapy, in particular for the subcutaneous delivery of said stable protein.
  • Immunoglobulins, monoclonal antibodies (mAbs) and humanized antibodies have been in development as pharmaceutical products for a number of years.
  • multi-dose formulations of mAbs must contain antimicrobial agents to protect them from microbial contamination during multiple dosage withdrawal.
  • Multi-dose formulations containing preservatives offer several advantages over single dose containers. For example, product wastage is minimized because different sized doses may be obtained from the same container. Additionally, doses may be obtained from the same container over a period of time without the concern for microbial growth.
  • packaging is minimized because multiple doses are supplied in a single vial.
  • Aggregate formation by a polypeptide during storage of a liquid pharmaceutical composition can adversely affect biological activity of that polypeptide, resulting in loss of therapeutic efficacy of the pharmaceutical composition. Furthermore, aggregate formation may cause other problems such as blockage of tubing, membranes, or pumps when the polypeptide-containing pharmaceutical composition is administered using an infusion system.
  • US 2004/0009168 (Kaisheva et al) describes a multidose IgG formulation comprising a preservative.
  • WO 2008/071394 (F. Hoffmann-La Roche) describes a stable pharmaceutical parenteral formulation containing an amyloid-beta peptide antibody.
  • US 2007/0053871 (Li et al) describes a stable pharmaceutical formulation comprising a protein or antibody, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.
  • WO 00/15224 (Eli Lilly and Company) describes a stable, soluble formulation comprising a protein, hydrophobic preservative and nicotinamide.
  • WO 2008/121615 (MedImmune, Inc) describes a high concentration liquid formulation of an antibody.
  • WO 2009/070642 MedImmune, Inc describes stable lyophilised formulations of bispecific antibodies.
  • US 2004/0197324 (Genentech, Inc) describes high concentration antibody and protein formulations with reduced viscosity, that are stable, relatively isotonic and are of low turbidity.
  • US 2008/0112953 (Amgen, Inc) describes a stable formulation comprising an EGFR antibody and a glutamic acid buffer.
  • U.S. Pat. No. 6,875,432 (Genentech, Inc) describes a concentrated protein formulation with reduced viscosity.
  • a stable, multi-dose liquid composition comprising an antibody and one or more preservatives.
  • a stable, multi-dose liquid composition as defined herein for use in therapy is provided.
  • a stable, multi-dose liquid composition comprising an antibody and one or more preservatives.
  • Benzyl alcohol has been demonstrated to bind to and accelerate aggregation of partially unfolded proteins.
  • a concentration of 1% benzyl alcohol resulted in cloudiness and the formation of soluble aggregates.
  • Concentrations of benzyl alcohol greater than 2% in the same monoclonal antibody formulation resulted in precipitation of the protein.
  • stable composition refers to a composition with satisfactory physical stability, satisfactory chemical stability or satisfactory physical and chemical stability.
  • the term “physical stability” of the protein composition as used herein refers to the tendency of the protein to form biologically inactive and/or insoluble aggregates of the protein as a result of exposure of the protein to thermo-mechanical stresses and/or interaction with interfaces and surfaces that are destabilizing, such as hydrophobic surfaces and interfaces.
  • Physical stability of the aqueous protein compositions is evaluated by means of visual inspection and/or turbidity measurements after exposing the composition filled in suitable containers (e.g. cartridges or vials) It is an inherent quality of highly concentrated formulations of mabs to exhibit opalescence due to Raleigh scattering. Thus, a composition cannot be classified as physically unstable with respect to protein aggregation, when it shows visual turbidity in daylight. However, when there are precipitates or phase separation visible in day light the formulation is classified as physically unstable.
  • chemical stability of the protein composition refers to chemical covalent changes in the protein structure leading to formation of chemical degradation products with potential less biological potency and/or potential increased immunogenic properties compared to the native protein structure.
  • chemical degradation products can be formed depending on the type and nature of the native protein and the environment to which the protein is exposed. Elimination of chemical degradation can most probably not be completely avoided and increasing amounts of chemical degradation products is often seen during storage and use of the protein composition is well-known by the person skilled in the art.
  • Most proteins are prone to deamidation, a process in which the side chain amide group in glutaminyl or asparaginyl residues is hydrolysed to form a free carboxylic acid.
  • Oxidation (of for instance methionine residues) can be mentioned as another variant of chemical degradation.
  • the chemical stability of the protein composition can be evaluated by measuring the amount of the chemical degradation products at various time-points after exposure to different environmental conditions (the formation of degradation products can often be accelerated by for instance increasing temperature).
  • the amount of each individual degradation product is often determined by separation of the degradation products depending on molecule size and/or charge using various chromatography techniques (e.g. SEC-HPLC and/or RP-HPLC).
  • SEC-HPLC is in particular used for quantification of protein aggregates.
  • the samples may for instance be analysed using a TSK G3000 SWXL column, isocratic elution and subsequent UV detection at 214 nm.
  • This method is used to determine monomeric IgG content and % High Molecular Weight Proteins (HMWP) consisting of dimeric species or larger which are separated according to size by the gel resin.
  • the monomeric content and % HMWP are determined relative to the total protein content detected by the method.
  • a stable composition refers to a composition with satisfactory physical stability, satisfactory chemical stability or satisfactory physical and chemical stability.
  • a satisfactory stability of a formulation may be measured by the increase of % High Molecular Weight Proteins ( ⁇ % HMWP).
  • ⁇ % HMWP % High Molecular Weight Proteins
  • a satisfactory stability of a formulation may be one wherein the increase is less than 10% and preferably less than 5% of the protein found as an aggregate ( ⁇ % HMWP) in the formulation over the testing period.
  • a composition must be stable during use and storage (in compliance with recommended use and storage conditions) until the expiration date is reached.
  • protein means a compound composed of at least five constituent amino acids connected by peptide bonds.
  • the constituent amino acids may be from the group of the amino acids encoded by the genetic code and they may be natural amino acids which are not encoded by the genetic code, as well as synthetic amino acids.
  • Natural amino acids which are not encoded by the genetic code are e.g. hydroxyproline, y-carboxyglutamate, ornithine, phosphoserine, D-alanine and D-glutamine.
  • Synthetic amino acids comprise amino acids manufactured by chemical synthesis, i.e.
  • D-isomers of the amino acids encoded by the genetic code such as D-alanine and D-leucine, Aib (a-aminoisobutyric acid), Abu ( ⁇ -aminobutyric acid), Tle (tert-butylglycine), ⁇ -alanine, 3-aminomethyl benzoic acid and anthranilic acid.
  • preservative refers to pharmaceutically acceptable excipients which prevent the growth of micro-organisms within the composition. More particularly, the invention provides a preservative containing multi-dose liquid composition which protects the composition against microbial contamination.
  • the preservative is present within the composition in an amount of between 0.001 to 2% (w/v). In one embodiment, the preservative is present within the composition in an amount of between 0.002 to 1% (w/v).
  • the one or more preservative is selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride, thiomersal or any combinations thereof.
  • the one or more preservative is selected from phenol, m-cresol, benzyl alcohol and chlorobutanol.
  • the composition comprises a single preservative. In one embodiment, the composition comprises a single preservative selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride and thiomersal.
  • phenol is typically present within the composition in an amount from 0.1 to 1% (w/v), such as 0.1 to 0.5% (w/v), such as 0.15 or 0.5% (w/v), in particular, 0.25 to 0.5% (w/v).
  • m-cresol is typically present within the composition in an amount from 0.1 to 1% (w/v), such as 0.1 to 0.5% (w/v), such as 0.15 or 0.35% (w/v), in particular, approximately 0.3% (w/v).
  • benzyl alcohol is typically present within the composition in an amount from 0.1 to 2% (w/v), such as 0.1 to 1.5% (w/v), such as 0.5 or 1.1% (w/v), in particular, approximately 1% (w/v).
  • chlorobutanol is typically present within the composition in an amount from 0.1 to 1% (w/v), such as 0.25 to 0.75% (w/v), such as 0.3 or 0.6% (w/v), in particular, approximately 0.3 to 0.5% (w/v).
  • methyl paraben is typically present within the composition in an amount from 0.1 to 0.5% (w/v), such as approximately 0.2% (w/v).
  • propyl paraben is typically present within the composition in an amount from 0.1 to 0.5% (w/v), such as approximately 0.2% (w/v).
  • phenoxyethanol is typically present within the composition in an amount from 0.1 to 2% (w/v), such as approximately 1% (w/v).
  • composition comprises thiomersal as a single preservative
  • thiomersal is typically present within the composition in an amount from 0.002 to 0.01% (w/v).
  • the composition comprises a single preservative selected from phenol, m-cresol, benzyl alcohol and chlorobutanol.
  • the composition comprises two or more preservatives. In one embodiment, the composition comprises two preservatives. Data is presented herein which surprisingly demonstrates that a lower amount of aggregates were observed for compositions comprising two preservatives when compared with the aggregation observed for the individual preservatives. In a yet further embodiment, the composition comprises two preservatives selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride and thiomersal.
  • the composition comprises two preservatives selected from phenol, m-cresol, benzyl alcohol and chlorobutanol.
  • preservatives selected from phenol, m-cresol, benzyl alcohol and chlorobutanol.
  • examples of such compositions comprising two preservatives include: phenol and m-cresol; and benzyl alcohol and chlorobutanol.
  • the concentration of each individual preservative will typically be lower than when a single preservative is used.
  • the composition comprises phenol and m-cresol as a two preservative containing composition
  • phenol is typically present within the composition in an amount from 0.1 to 0.75% (w/v), such as 0.1 to 0.5% (w/v), e.g. 0.15 or 0.5% (w/v)
  • m-cresol is typically present within the composition in an amount from 0.1 to 0.5% (w/v), such as 0.15 to 0.4% (w/v), e.g. 0.18 or 0.35% (w/v).
  • composition comprises benzyl alcohol and chlorobutanol as a two preservative containing composition
  • benzyl alcohol is typically present within the composition in an amount from 0.25 to 1% (w/v), such as 0.4 to 0.9% (w/v), e.g. 0.5 or 0.8% (w/v)
  • chlorobutanol is typically present within the composition in an amount from 0.1 to 0.5% (w/v), such as 0.1 to 0.4% (w/v), e.g. 0.11 or 0.3% (w/v).
  • the composition additionally comprises a salt.
  • the salt can have a buffering capacity at the relevant pH.
  • the salt is an inorganic salt, or an organic salt or a combination of one or more of these.
  • the salt is selected from the group consisting of sodium chloride, magnesium chloride, sodium thiocyanate, ammonium thiocyanate, ammonium sulfate, ammonium chloride, calcium chloride, arginine hydrochloride, zinc chloride, sodium acetate, amino acids or a combination thereof.
  • the salt is sodium chloride or magnesium chloride, optionally in combination with other salts.
  • the salt is arginine hydrochloride.
  • the salt is a combination of an inorganic salt and arginine hydrochloride.
  • the salt is an amino acid. In one embodiment the L-stereoisomer of the amino acid is used. In one embodiment, the salt is selected from arginine, glycine, lysine, aspartic acid, or glutamic acid, or a combination thereof. In one embodiment, the amino acid is arginine or glycine. In one embodiment, the amino acid is arginine, such as L-arginine. The amino acid can be added to the composition in its salt form or in its free form, whatever is suitable.
  • the composition additionally comprises a buffer.
  • the buffer is a suitable pharmaceutically acceptable buffer, which comprises both a pharmaceutically acceptable base and a pharmaceutically acceptable acid.
  • the buffer has a pKa of between 4 and 8, such as 5 to 7.
  • the buffer may be a salt.
  • Examples of pharmaceutically acceptable acid and bases may include inorganic as well as organic non-toxic acid/bases such as is well-known in the art. Examples are dosodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, maleate, succinate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-amino methane, or mixtures thereof. Each one of these specific buffers constitutes an alternative embodiment of the invention.
  • the pharmaceutically acceptable buffer comprises histidine, maleate, succinate, phosphate, or tris(hydroxymethyl)-amino methane.
  • the pharmaceutically acceptable buffer comprises histidine.
  • the buffer has a pKa value ⁇ 1 pH unit from the target pH of the composition.
  • the composition is buffered to a pH of between 5 and 7, such as a pH of 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 or 7.0, or to a pH as defined by any ranges there between.
  • the composition is buffered to a pH of between 6.0 and 7.0, such as 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 or 7.0, or to a pH as defined by any ranges there between.
  • the composition is buffered to a pH of between 6.0 and 6.5.
  • the composition is buffered to a pH of 6.0 or 6.5, such as 6.5.
  • the composition additionally comprises a surfactant.
  • the surfactant is selected from a detergent, ethoxylated castor oil, polyglycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, polyoxypropylene-polyoxyethylene block polymers (eg. poloxamers such as Pluronic® F68, poloxamer 188 and 407, Triton X-100), polyoxyethylene sorbitan fatty acid esters, polyoxyethylene and polyethylene derivatives such as alkylated and alkoxylated derivatives (Polysorbates, e.g.
  • Tween-20, Tween-40, Tween-80 and Brij-35 monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, alcohols, glycerol, lectins and phospholipids (eg. phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, diphosphatidyl glycerol and sphingomyelin), derivates of phospholipids (eg. dipalmitoyl phosphatidic acid) and lysophospholipids (eg.
  • phospholipids eg. dipalmitoyl phosphatidic acid
  • lysophospholipids eg.
  • ceramides e.g. sodium tauro-dihydrofusidate etc.
  • C6-C12 e.g.
  • acylcarnitines and derivatives N ⁇ -acylated derivatives of lysine, arginine or histidine, or side-chain acylated derivatives of lysine or arginine, N ⁇ -acylated derivatives of dipeptides comprising any combination of lysine, arginine or histidine and a neutral or acidic amino acid, N ⁇ -acylated derivative of a tripeptide comprising any combination of a neutral amino acid and two charged amino acids, DSS (docusate sodium, CAS registry no [577-11-7]), docusate calcium, CAS registry no [128-49-4]), docusate potassium, CAS registry no [7491-09-0]), SDS (sodium dodecyl sulphate or sodium lauryl sulphate), sodium caprylate, cholic acid or derivatives thereof, bile acids and salts thereof and glycine or taurine conjugates
  • DSS docusate sodium, CAS
  • N-alkyl-N,N-dimethylammonio-1-propanesulfonates 3-cholamido-1-propyldimethylammonio-1-propanesulfonate
  • cationic surfactants quaternary ammonium bases
  • cetyl-trimethylammonium bromide cetylpyridinium chloride
  • non-ionic surfactants eg. Dodecyl ⁇ -D-glucopyranoside
  • poloxamines eg.
  • Tetronic's which are tetrafunctional block copolymers derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine, or the surfactant may be selected from the group of imidazoline derivatives, or mixtures thereof. Each one of these specific surfactants constitutes an alternative embodiment of the invention.
  • the surfactant is Tween 80 (i.e. polysorbate 80).
  • the surfactant is present within the composition in an amount of below 0.01%. In one embodiment, the surfactant is present within the composition in an amount of below 0.0075%, i.e between 0.001% and 0.005%, such as 0.001%. In one embodiment, no surfactant is present.
  • the composition additionally comprises a tonicity modifying agent.
  • suitable tonicity modifying agents include salts (e.g sodium chloride), polyhydric alcohols (e.g propyleneglycol, glycerol, xyllitol. mannitol or D-sorbitol), monosaccarides (glucose or maltose), di saccarides (e.g sucrose), amino acids (L-glycine, L-histidine, arginine, lysine, isoleucine, aspartic acid, tryptophane, threonine), polyethylen glycols (e.g PEG 400) or mixtures thereof.
  • salts e.g sodium chloride
  • polyhydric alcohols e.g propyleneglycol, glycerol, xyllitol. mannitol or D-sorbitol
  • monosaccarides glucose or maltose
  • di saccarides e.
  • the tonicity modifying agent is sucrose, mannitol or propylene glycol. In one embodiment, the tonicity modifying agent is sucrose.
  • the buffer and/or salt of the composition also acts as a tonicity modifier or the tonicity modifier will act as a buffer and/or salt (and the concentration of the tonicity modifier will therefore in such cases be calculated as such).
  • the tonicity modifying agent is present within the composition in an amount of between 50 and 250 mM, such as between 100 and 200 mM, for example any one of 100, 110, 120, 130, 140, 150, 160, 170, 180, 190 or 200 or any ranges there between. In one embodiment, the tonicity modifying agent is present within the composition in an amount of 150 mM.
  • the composition is isotonic.
  • a stable, multi-dose liquid composition comprising a protein and one or more preservatives.
  • the protein is an immunoglobulin. In one embodiment, the protein is an antibody. In one embodiment, the protein is a monoclonal antibody (mAb). In one embodiment, the protein is an IgG4 antibody.
  • antibody covers monoclonal antibodies (including full length antibodies which have an immunoglobulin Fc region), antibody compositions with polyepitopic specificity, bispecific antibodies, diabodies, and single-chain molecules, as well as antibody fragments (e.g., Fab, F(ab′) 2 , and Fv).
  • the term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins.
  • the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • Suitable antibodies which may be formulated in a stable composition of the invention include: 3F8, Abagovomab, Abciximab, ACZ885 (canakinumab), Adalimumab, Adecatumumab, Afelimomab, Afutuzumab, Alacizumab pegol, Alemtuzumab, Altumomab pentetate, Anatumomab mafenatox, Anrukinzumab (IMA-638), Apolizumab, Arcitumomab, Aselizumab, Atlizumab (tocilizumab), Atorolimumab, Bapineuzumab, Basiliximab, Bavituximab, Bectumomab, Belimumab, Bertilimumab, Besilesomab, Bevacizumab, Biciromab, Bivatuzumab mertansine, Blinatum
  • the antibody is selected from an Anti-IL-20, Anti-TFPI, Anti-IL-21, Anti-C5Ar, Anti-NKGDA or Anti-NKG2a antibody.
  • the antibody is a monoclonal Anti-IL-20 antibody. In one embodiment, the antibody is an Anti-IL-20 antibody as described in WO 2010/000721. In one embodiment, the Anti-IL-20 monoclonal antibody is 15D2 or 5B7 as described in WO 2010/000721.
  • the antibody is a monoclonal Anti-TFPI antibody. In one embodiment, the antibody is an Anti-TFPI antibody as described in PCT/EP2009/067598. In one embodiment, the Anti-TFPI monoclonal antibody is HzTFPI4F36 as described in PCT/EP2009/067598.
  • the protein is present within the composition in high concentrations.
  • the protein is present in a concentration of 50 mg/ml or more, such as 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300 mg/ml or more.
  • the protein is present within the composition in an amount of between 50 mg/ml and 300 mg/ml, for instance between 50 mg/ml and 250 mg/ml, such as between 50 mg/ml and 200 mg/ml, for instance between 50 mg/ml and 150 mg/ml.
  • the protein is present in a concentration of between 75 mg/ml and 300 mg/ml, for instance between 75 mg/ml and 250 mg/ml, such as between 75 mg/ml and 200 mg/ml, for instance between 75 mg/ml and 150 mg/ml. In one embodiment, the protein is present in a concentration of between 100 mg/ml and 300 mg/ml, for instance between 100 mg/ml and 250 mg/ml, such as between 100 mg/ml and 200 mg/ml, for instance between 100 mg/ml and 150 mg/ml.
  • a protein composition of the invention comprises:
  • a protein composition of the invention comprises:
  • a protein composition of the invention comprises:
  • a protein composition of the invention comprises:
  • a protein composition of the invention comprises:
  • compositions of the invention have surprisingly demonstrated stability towards formation of high molecular weight proteins (HMWP) at 40° C. for 4 weeks and at 5° C. and 40° C. for 3 months.
  • HMWP high molecular weight proteins
  • a pharmaceutical formulation comprising the antibody and the excipients (including one or more preservatives) is prepared.
  • the pharmaceutical compositions of the invention are stable for more than 6 weeks of usage and for more than 3 years of storage.
  • the pharmaceutical compositions of the invention are stable for more than 4 weeks of usage and for more than 3 years of storage.
  • the pharmaceutical compositions of the invention are stable for more than 4 weeks of usage and for more than 2 years of storage.
  • the pharmaceutical compositions of the invention are stable for more than 2 weeks of usage and for more than 2 years of storage.
  • the pharmaceutical compositions of the invention are stable for more than 1 week of usage and for more than 6 months of storage.
  • a stable, multi-dose liquid composition as defined herein for use in therapy is provided.
  • treatment means the management and care of a patient for the purpose of combating a condition, such as a disease or a disorder.
  • the term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to alleviate or relieve the symptoms and complications, and/or to cure or eliminate the disease, disorder or condition as well as to prevent the condition, wherein prevention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications.
  • the patient to be treated is preferably a mammal; in particular a human being, but it may also include animals, such as dogs, cats, cows, sheep and pigs.
  • the stable compositions of Anti-IL-20 antibodies of the present invention may be used in the treatment of an inflammatory disease, in particular autoinflammatory diseases, such as psoriasis, systemic lupus erythomatosus, rheumatoid arthritis, Crohn's disease and psoriatic arthritis or otherwise as described in WO 2010/000721.
  • autoinflammatory diseases such as psoriasis, systemic lupus erythomatosus, rheumatoid arthritis, Crohn's disease and psoriatic arthritis or otherwise as described in WO 2010/000721.
  • the invention provides a method of treating such an inflammatory disease which comprises administering to a patient a therapeutically effective amount of a stable composition of an Anti-IL-20 antibody of the present invention.
  • the invention also provides a stable composition of an Anti-IL-20 antibody of the present invention for use in the treatment of such an inflammatory disease.
  • the invention also provides the use of a stable composition of an Anti-IL-20 antibody of the present invention in the manufacture of a medicament for the treatment of such an inflammatory disease.
  • the invention also provides a stable pharmaceutical composition comprising a stable composition of an Anti-IL-20 antibody of the present invention for use in the treatment of such an inflammatory disease.
  • compositions of Anti-TFPI antibodies of the present invention may be used in the treatment of a coagulopathy (bleeding disorder), such as haemophilia A, with or without inhibitors, and haemophilia B, with or without inhibitors or otherwise as described in PCT/EP2009/067598.
  • a coagulopathy bleeding disorder
  • haemophilia A with or without inhibitors
  • haemophilia B with or without inhibitors or otherwise as described in PCT/EP2009/067598.
  • the invention provides a method of treating a coagulopathy which comprises administering to a patient a therapeutically effective amount of a stable composition of an Anti-TFPI antibody of the present invention.
  • the invention also provides a stable composition of an Anti-TFPI antibody of the present invention for use in the treatment of a coagulopathy.
  • the invention also provides the use of a stable composition of an Anti-TFPI antibody of the present invention in the manufacture of a medicament for the treatment of a coagulopathy.
  • the invention also provides a pharmaceutical composition comprising a stable composition of an Anti-TFPI antibody of the present invention for use in the treatment of a coagulopathy.
  • parenteral administration may be performed by subcutaneous, intramuscular, intraperitoneal or intravenous injection by means of a syringe, optionally a pen-like syringe.
  • parenteral administration can be performed by means of an infusion pump.
  • the formulations were prepared (see Table 1 below). The formulations were prepared from a stock solution containing ca. 150 mg/ml of the Anti-IL-20 antibody and 10 mM histidine buffer, pH 6.5. This stock solution was prepared by conventional UF/DF/UF. Stock solution of the excipients were prepared and mixed in the correct proportion. The final formulations were filled in 3 ml Penfill® cartridges, type 1 glass. The formulations were stored at 40° C. for 4 weeks and then analysed chemically, pharmaceutically and biophysically. The increase in the formation of protein aggregates (% HMWP) was measured by SEC-HPLC (as described above).
  • compositions containing 2 preservatives generally resulted in lower aggregate formation than the results achieved with the individual preservatives alone.
  • the composition containing 5 mg/ml phenol alone resulted in an increase of 2.5% HMWP
  • the composition containing 3.5 mg/ml m-cresol alone resulted in an increase of 3.1% HMWP
  • a composition containing a combination of these two preservatives at identical concentrations resulted in a lowering of aggregate formation (an increase of 1.2% HMWP).
  • An increase of 1.1% is seen for reference without preservative.
  • composition containing 3.5 mg/ml m-cresol resulted in the smallest increase in HMWP. After 3 months storage the increase in HMWP for this formulation is lower compared to reference without preservative.
  • composition containing phenol and m-cresol, respectively showed no increase in % HMWP over a period of 12 months at 5° C.
  • a preservative efficacy screening test was performed.
  • the efficacy of the preservative was measured using a modified USP/Ph Eur preservative efficacy test.
  • formulations were tested against Staphylococcus aureus . After inoculation, samples were stored for 6 and 24 hours at room temperature and the total bacterial counts were measured using a colony counter. The log reduction values were calculated as log (initial count/final count).
  • Embodiment 1 A stable, multi-dose liquid composition comprising an antibody and one or more preservatives.
  • Embodiment 2 A composition according to embodiment 1, wherein the preservative is present within the composition in an amount of between 0.001 to 2% (w/v).
  • Embodiment 3 A composition according to embodiment 1 or 2, wherein the preservative is present within the composition in an amount of between 0.002 to 1% (w/v).
  • Embodiment 4 A composition according to any of embodiments 1 to 3, wherein the one or more preservative is selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride, thiomersal or any combinations thereof.
  • the one or more preservative is selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride, thiomersal or any combinations thereof.
  • Embodiment 5 A composition according to any of embodiments 1 to 4, wherein the one or more preservative is selected from phenol, m-cresol, benzyl alcohol and chlorobutanol.
  • Embodiment 6 A composition according to any of embodiments 1 to 5, wherein the composition comprises a single preservative.
  • Embodiment 7 A composition according to any of embodiments 1 to 6, wherein the composition comprises a single preservative selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride and thiomersal.
  • a single preservative selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride and thiomersal.
  • Embodiment 8 A composition according to any of embodiments 1 to 7, which comprises phenol as a single preservative, wherein said phenol is present within the composition in an amount from 0.1 to 1% (w/v).
  • Embodiment 9 A composition according to any of embodiments 1 to 7, which comprises phenol as a single preservative, wherein said phenol is present within the composition in an amount from 0.1 to 0.5% (w/v).
  • Embodiment 10 A composition according to any of embodiments 1 to 7, which comprises phenol as a single preservative, wherein said phenol is present within the composition in an amount of 0.15 or 0.5% (w/v).
  • Embodiment 11 A composition according to any of embodiments 1 to 7, which comprises phenol as a single preservative, wherein said phenol is present within the composition in an amount from 0.25 to 0.5% (w/v).
  • Embodiment 12 A composition according to any of embodiments 1 to 7, which comprises m-cresol as a single preservative, wherein said m-cresol is present within the composition in an amount from 0.1 to 1% (w/v).
  • Embodiment 13 A composition according to any of embodiments 1 to 7, which comprises m-cresol as a single preservative, wherein said m-cresol is present within the composition in an amount from 0.1 to 0.5% (w/v).
  • Embodiment 14 A composition according to any of embodiments 1 to 7, which comprises m-cresol as a single preservative, wherein said m-cresol is present within the composition in an amount of 0.15 or 0.35% (w/v).
  • Embodiment 15 A composition according to any of embodiments 1 to 7, which comprises m-cresol as a single preservative, wherein said m-cresol is present within the composition in an amount of approximately 0.3% (w/v).
  • Embodiment 16 A composition according to any of embodiments 1 to 7, which comprises benzyl alcohol as a single preservative, wherein said benzyl alcohol is present within the composition in an amount from 0.1 to 2% (w/v).
  • Embodiment 17 A composition according to any of embodiments 1 to 7, which comprises benzyl alcohol as a single preservative, wherein said benzyl alcohol is present within the composition in an amount from 0.1 to 1.5% (w/v).
  • Embodiment 18 A composition according to any of embodiments 1 to 7, which comprises benzyl alcohol as a single preservative, wherein said benzyl alcohol is present within the composition in an amount of 0.5 or 1.1% (w/v).
  • Embodiment 19 A composition according to any of embodiments 1 to 7, which comprises benzyl alcohol as a single preservative, wherein said benzyl alcohol is present within the composition in an amount of approximately 1% (w/v).
  • Embodiment 20 A composition according to any of embodiments 1 to 7, which comprises chlorobutanol as a single preservative, wherein said chlorobutanol is present within the composition in an amount from 0.1 to 1% (w/v).
  • Embodiment 21 A composition according to any of embodiments 1 to 7, which comprises chlorobutanol as a single preservative, wherein said chlorobutanol is present within the composition in an amount from 0.25 to 0.75% (w/v).
  • Embodiment 22 A composition according to any of embodiments 1 to 7, which comprises chlorobutanol as a single preservative, wherein said chlorobutanol is present within the composition in an amount of 0.3 or 0.6% (w/v).
  • Embodiment 23 A composition according to any of embodiments 1 to 7, which comprises chlorobutanol as a single preservative, wherein said chlorobutanol is present within the composition in an amount from 0.3 to 0.5% (w/v).
  • Embodiment 24 A composition according to any of embodiments 1 to 7, which comprises methyl paraben as a single preservative, wherein said methyl paraben is present within the composition in an amount from 0.1 to 0.5% (w/v).
  • Embodiment 25 A composition according to any of embodiments 1 to 7, which comprises methyl paraben as a single preservative, wherein said methyl paraben is present within the composition in an amount of approximately 0.2% (w/v).
  • Embodiment 26 A composition according to any of embodiments 1 to 7, which comprises propyl paraben as a single preservative, wherein said propyl paraben is present within the composition in an amount from 0.1 to 0.5% (w/v).
  • Embodiment 27 A composition according to any of embodiments 1 to 7, which comprises propyl paraben as a single preservative, wherein said propyl paraben is present within the composition in an amount of approximately 0.2% (w/v).
  • Embodiment 28 A composition according to any of embodiments 1 to 7, which comprises phenoxyethanol as a single preservative, wherein said phenoxyethanol is present within the composition in an amount from 0.1 to 2% (w/v).
  • Embodiment 29 A composition according to any of embodiments 1 to 7, which comprises phenoxyethanol as a single preservative, wherein said phenoxyethanol is present within the composition in an amount of approximately 1% (w/v).
  • Embodiment 30 A composition according to any of embodiments 1 to 7, which comprises thiomersal as a single preservative, wherein said thiomersal is present within the composition in an amount from 0.002 to 0.01% (w/v).
  • Embodiment 31 A composition according to any of embodiments 1 to 7, which comprises a single preservative selected from phenol, m-cresol, benzyl alcohol and chlorobutanol.
  • Embodiment 32 A composition according to any of embodiments 1 to 5, which comprises two or more preservatives.
  • Embodiment 33 A composition according to embodiment 32, which comprises two preservatives.
  • Embodiment 34 A composition according to embodiment 32 or 33, which comprises two preservatives selected from phenol, m-cresol, benzyl alcohol, chlorobutanol, ethanol, phenoxyethanol, p-chlor-m-cresol, methyl paraben, propyl paraben, benzalkonium chloride and thiomersal.
  • Embodiment 35 A composition according to embodiment 34, which comprises two preservatives selected from phenol, m-cresol, benzyl alcohol and chlorobutanol.
  • Embodiment 36 A composition according to any of embodiments 32 to 35, wherein said two preservatives are phenol and m-cresol.
  • Embodiment 37 A composition according to embodiment 36, wherein phenol is present within the composition in an amount from 0.1 to 0.75% (w/v).
  • Embodiment 38 A composition according to embodiment 36 or 37, wherein phenol is present within the composition in an amount from 0.1 to 0.5% (w/v).
  • Embodiment 39 A composition according to any of embodiments 36 to 38, wherein phenol is present within the composition in an amount of 0.15 or 0.5% (w/v).
  • Embodiment 40 A composition according to any of embodiments 36 to 39, wherein m-cresol is present within the composition in an amount from 0.1 to 0.5% (w/v).
  • Embodiment 41 A composition according to any of embodiments 36 to 40, wherein m-cresol is present within the composition in an amount from 0.15 to 0.4% (w/v).
  • Embodiment 42 A composition according to any of embodiments 36 to 41, wherein m-cresol is present within the composition in an amount of 0.18 or 0.35% (w/v).
  • Embodiment 43 A composition according to any of embodiments 32 to 35, wherein said two preservatives are benzyl alcohol and chlorobutanol.
  • Embodiment 44 A composition according to embodiment 43, wherein benzyl alcohol is present within the composition in an amount from 0.25 to 1% (w/v).
  • Embodiment 45 A composition according to embodiment 43 or 44, wherein benzyl alcohol is present within the composition in an amount from 0.4 to 0.9% (w/v).
  • Embodiment 46 A composition according to any of embodiments 43 to 45, wherein benzyl alcohol is present within the composition in an amount of 0.5 or 0.8% (w/v).
  • Embodiment 47 A composition according to any of embodiments 43 to 46, wherein chlorobutanol is present within the composition in an amount from 0.1 to 0.5% (w/v).
  • Embodiment 48 A composition according to any of embodiments 43 to 47, wherein chlorobutanol is present within the composition in an amount from 0.1 to 0.4% (w/v).
  • Embodiment 49 A composition according to any of embodiments 43 to 48, wherein chlorobutanol is present within the composition in an amount of 0.11 or 0.3% (w/v).
  • Embodiment 50 A composition according to any embodiments 1 to 49, wherein a buffer is present, and the buffer has a pKa between 4 to 8.
  • Embodiment 51 A composition according to embodiment 50, wherein the buffer has a pKa between 5 to 7.
  • Embodiment 52 A composition according to embodiment 50 or 51, wherein a buffer is present, and the buffer is dosodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, maleate, succinate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, or tris(hydroxymethyl)-amino methane, or mixtures thereof.
  • a buffer is present, and the buffer is dosodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, maleate, succinate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, or tris(hydroxymethyl)-amino methane, or mixtures thereof.
  • Embodiment 53 A composition according to embodiment 52, wherein the buffer is histidine, maleate, succinate, phosphate, or tris(hydroxymethyl)-amino methane.
  • Embodiment 54 A composition according to embodiment 53, wherein the buffer is histidine.
  • Embodiment 55 A composition according to embodiment 54, wherein the buffer has a pKa value ⁇ 1 pH unit from the target pH of the composition.
  • Embodiment 56 A composition according to any of embodiments 1 to 55, wherein a salt is present and the salt is selected from the group consisting of sodium chloride, magnesium chloride, sodium thiocyanate, ammonium thiocyanate, ammonium sulfate, ammonium chloride, calcium chloride, arginine hydrochloride, zinc chloride and sodium acetate or any combination thereof.
  • Embodiment 57 A composition according to embodiment 56, wherein the salt is sodium chloride or magnesium chloride.
  • Embodiment 58 A composition according to embodiment 57, wherein the salt is sodium chloride.
  • Embodiment 59 A composition according to embodiment 56, wherein the salt is arginine-HCl.
  • Embodiment 60 A composition according to any of embodiments 1 to 59, which has a pH of between 5.0 and 7.0.
  • Embodiment 61 A composition according to embodiment 60, which has a pH of between 6.0 and 7.0.
  • Embodiment 62 A composition according to embodiment 61, which has a pH of 6.0 or 6.5.
  • Embodiment 63 A composition according to embodiment 62, which has a pH of 6.5.
  • Embodiment 64 A composition according to any of embodiments 1 to 63 which additionally comprises a surfactant.
  • Embodiment 65 A composition according to embodiment 64, wherein the surfactant is Tween 80 (i.e. polysorbate 80).
  • Embodiment 66 A composition according to embodiment 64 or 65, wherein the surfactant is present within the composition in an amount of below 0.01%.
  • Embodiment 67 A composition according to any of embodiments 64 to 66, wherein the surfactant is present within the composition in an amount of below 0.0075%.
  • Embodiment 68 A composition according to any of embodiments 64 to 67, wherein the surfactant is present within the composition in an amount between 0.001% and 0.005%.
  • Embodiment 69 A composition according to any of embodiments 64 to 68, wherein the surfactant is present within the composition in an amount of 0.001%.
  • Embodiment 70 A composition according to any of embodiments 1 to 63 wherein no surfactant is present.
  • Embodiment 71 A composition according to any of embodiments 1 to 70, which additionally comprises a tonicity modifying agent.
  • Embodiment 72 A composition according to embodiment 71, wherein the tonicity modifying agent is sucrose or propylene glycol.
  • Embodiment 73 A composition according to embodiment 72, wherein the tonicity modifying agent is sucrose.
  • Embodiment 74 A composition according to embodiment 72, wherein the tonicity modifying agent is propylene glycol.
  • Embodiment 75 A composition according to any of embodiments 71 to 74, wherein the tonicity modifying agent is present within the composition in an amount of between 50 and 250 mM.
  • Embodiment 76 A composition according to any of embodiments 71 to 75, wherein the tonicity modifying agent is present within the composition in an amount of between 100 and 200 mM.
  • Embodiment 77 A composition according to any of embodiments 71 to 76, wherein the tonicity modifying agent is present in an amount of 100 mM.
  • Embodiment 78 A composition according to any of embodiments 1 to 77, wherein the composition is pharmaceutically acceptable.
  • Embodiment 79 A stable composition according to any of embodiments 1 to 78,
  • the antibody is present within the composition in a concentration of between 50 mg/ml and 300 mg/ml.
  • Embodiment 80 A stable composition according to embodiment 79, wherein the antibody is present within the composition in a concentration of between 75 mg/ml and 300 mg/ml.
  • Embodiment 81 A stable composition according to embodiment 80, wherein the antibody is present within the composition in a concentration of between 100 mg/ml and 300 mg/ml.
  • Embodiment 82 A stable composition according to embodiment 81, wherein the antibody is present within the composition in a concentration of between 50 mg/ml and 200 mg/ml.
  • Embodiment 83 A stable composition according to embodiment 82, wherein the antibody is present within the composition in a concentration of 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, or 300 mg/ml.
  • Embodiment 84 A composition according to embodiment 1 which comprises:
  • Embodiment 85 A composition according to embodiment 1 which comprises:
  • Embodiment 86 A composition according to embodiment 1 which comprises:
  • Embodiment 87 A composition according to embodiment 1 which comprises:
  • Embodiment 88 A composition according to embodiment 1 which comprises:
  • Embodiment 89 A composition according to embodiment 1 which comprises:
  • Embodiment 90 A composition according to embodiment 1 which comprises:
  • Embodiment 91 A composition according to embodiment 1 which comprises:
  • Embodiment 92 A composition according to embodiment 1 which comprises:
  • Embodiment 93 A composition according to embodiment 1 which comprises:
  • Embodiment 94 A composition according to embodiment 1 which comprises:
  • Embodiment 95 A composition according any of embodiments 1-94, wherein the antibody is of the IgG4 subtype.
  • Embodiment 96 A composition according to any of embodiments 1 to 95, wherein the antibody is a monoclonal antibody.
  • Embodiment 97 A composition according to embodiment 96, wherein the monoclonal antibody is an Anti-IL-20 monoclonal antibody.
  • Embodiment 98 A composition according to embodiment 96, wherein the monoclonal antibody is an Anti-IL-20 monoclonal antibody as described in WO 2010/000721.
  • Embodiment 99 A composition according to embodiment 96, wherein the monoclonal antibody is an Anti-IL-20 antibody 15D2 or 5B7 as described in WO 2010/000721.
  • Embodiment 100 A composition according to embodiment 96, wherein the monoclonal antibody is an Anti-TFPI monoclonal antibody.
  • Embodiment 101 A composition according to embodiment 96, wherein the monoclonal antibody is the Anti-TFPI monoclonal antibody HzTFPI4F36 as described in PCT/EP2009/067598.
  • Embodiment 102 A stable, multi-dose liquid composition according to any of embodiments 1 to 101 for use in therapy.
  • Embodiment 103 A method of treating an inflammatory disease which comprises administering to a patient a therapeutically effective amount of a composition according to any of embodiments 97-99.
  • Embodiment 104 A composition according to any of embodiments 97-99 for use in the treatment of an inflammatory disease.
  • Embodiment 105 Use of a composition according to any of embodiments 97-99 in the manufacture of a medicament for the treatment of an inflammatory disease.
  • Embodiment 106 A pharmaceutical composition comprising an Anti-IL-20 composition according to any of embodiments 97-99 for use in the treatment of an inflammatory disease.
  • Embodiment 107 A method of treating a coagulopathy which comprises administering to a patient a therapeutically effective amount of a composition according to any of embodiments 100-101.
  • Embodiment 108 A composition according to any of embodiments 100-101 for use in the treatment of a coagulopathy.
  • Embodiment 109 Use of a composition according to any of embodiments 100-101 in the manufacture of a medicament for the treatment of a coagulopathy.
  • Embodiment 110 A pharmaceutical composition comprising an Anti-TFPI composition according to any of embodiments 100-101 for use in the treatment of a coagulopathy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US13/699,847 2010-05-28 2011-05-26 Stable Multi-Dose Compositions Comprising an Antibody and a Preservative Abandoned US20130136733A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/699,847 US20130136733A1 (en) 2010-05-28 2011-05-26 Stable Multi-Dose Compositions Comprising an Antibody and a Preservative

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10164298 2010-05-28
EP10164298.1 2010-05-28
US35152210P 2010-06-04 2010-06-04
PCT/EP2011/058648 WO2011147921A1 (en) 2010-05-28 2011-05-26 Stable multi-dose compositions comprising an antibody and a preservative
US13/699,847 US20130136733A1 (en) 2010-05-28 2011-05-26 Stable Multi-Dose Compositions Comprising an Antibody and a Preservative

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/058648 A-371-Of-International WO2011147921A1 (en) 2010-05-28 2011-05-26 Stable multi-dose compositions comprising an antibody and a preservative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/799,276 Continuation US10835602B2 (en) 2010-05-28 2017-10-31 Stable multi-dose compositions comprising an antibody and a preservative

Publications (1)

Publication Number Publication Date
US20130136733A1 true US20130136733A1 (en) 2013-05-30

Family

ID=42562357

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/699,847 Abandoned US20130136733A1 (en) 2010-05-28 2011-05-26 Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
US15/799,276 Active US10835602B2 (en) 2010-05-28 2017-10-31 Stable multi-dose compositions comprising an antibody and a preservative

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/799,276 Active US10835602B2 (en) 2010-05-28 2017-10-31 Stable multi-dose compositions comprising an antibody and a preservative

Country Status (14)

Country Link
US (2) US20130136733A1 (enrdf_load_stackoverflow)
EP (1) EP2575761B1 (enrdf_load_stackoverflow)
JP (3) JP6294075B2 (enrdf_load_stackoverflow)
KR (1) KR20130086144A (enrdf_load_stackoverflow)
CN (2) CN105055306B (enrdf_load_stackoverflow)
AU (1) AU2011257219B2 (enrdf_load_stackoverflow)
BR (1) BR112012030139A2 (enrdf_load_stackoverflow)
CA (1) CA2800188A1 (enrdf_load_stackoverflow)
ES (1) ES2993022T3 (enrdf_load_stackoverflow)
HR (1) HRP20241526T1 (enrdf_load_stackoverflow)
MX (1) MX2012013586A (enrdf_load_stackoverflow)
RS (1) RS66182B1 (enrdf_load_stackoverflow)
RU (1) RU2012153786A (enrdf_load_stackoverflow)
WO (1) WO2011147921A1 (enrdf_load_stackoverflow)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9795674B2 (en) 2010-02-26 2017-10-24 Novo Nordisk A/S Stable antibody containing compositions
US9849181B2 (en) 2012-08-31 2017-12-26 Bayer Healthcare Llc High concentration antibody and protein formulations
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
US10835602B2 (en) 2010-05-28 2020-11-17 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
WO2021094917A1 (en) * 2019-11-13 2021-05-20 Pfizer Inc. Stable aqueous anti-tfpi antibody formulation

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2561828T3 (es) 2002-01-25 2016-03-01 Novo Nordisk A/S Anticuerpos monoclonales contra bucles extracelulares de C5aR
ES2562627T3 (es) 2008-02-20 2016-03-07 Novo Nordisk A/S Anticuerpos anti-C5aR humanizados
AU2009265808B2 (en) 2008-06-30 2014-10-23 Novo Nordisk A/S Anti-human interleukin-20 antibodies
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
EP3424953B1 (en) 2011-06-06 2020-08-05 Novo Nordisk A/S Therapeutic antibodies
US10160808B2 (en) * 2012-02-16 2018-12-25 Santarus, Inc. Anti-VLA1 (CD49A) antibody pharmaceutical compositions
ES2702246T3 (es) * 2012-03-26 2019-02-28 Sanofi Sa Formulaciones de agente de unión IgG4 estables
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
KR20230074843A (ko) 2015-08-19 2023-05-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
UY37726A (es) * 2017-05-05 2018-11-30 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
AU2019339344A1 (en) 2018-09-12 2021-03-18 Silverback Therapeutics, Inc. Compositions for the treatment of disease with immune stimulatory conjugates
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
WO2020257407A1 (en) 2019-06-19 2020-12-24 Silverback Therapeutics, Inc. Anti-mesothelin antibodies and immunoconjugates thereof
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
AU2021300362A1 (en) 2020-07-01 2023-02-23 ARS Pharmaceuticals, Inc. Anti-ASGR1 antibody conjugates and uses thereof
WO2022033981A1 (en) 2020-08-12 2022-02-17 Innate Pharma Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab
US20230357432A1 (en) * 2020-09-24 2023-11-09 Novo Nordisk Health A/S Pharmaceutical formulation of concizumab and method of production thereof
CN112244025A (zh) * 2020-11-27 2021-01-22 上海创宏生物科技有限公司 大分子蛋白和/或核酸用无菌处理剂及其制备方法和应用
AU2023367497A1 (en) * 2022-10-26 2025-05-15 Nihon Medi-Physics Co., Ltd. Radioactive pharmaceutical composition
US20240366471A1 (en) * 2023-05-01 2024-11-07 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US20020099179A1 (en) 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JP3681206B2 (ja) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
WO1998000870A1 (en) 1996-06-28 1998-01-08 Seiko Epson Corporation Thin film transistor, method of its manufacture and circuit and liquid crystal display using the thin film transistor
US5985614A (en) 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
PT963377E (pt) 1996-08-30 2009-05-11 Human Genome Sciences Inc Interleucina 19
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6486301B1 (en) 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
JP2001510035A (ja) 1997-07-16 2001-07-31 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド インターロイキン−２０
WO1999007740A2 (en) 1997-08-06 1999-02-18 Zymogenetics, Inc. Lipocalin homologs
US6576743B1 (en) 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
ES2226335T3 (es) 1998-01-23 2005-03-16 Immunex Corporation Receooctires de uk.18.
EP1062332A2 (en) 1998-03-09 2000-12-27 Schering Corporation Human receptor proteins; related reagents and methods
NZ507435A (en) 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
AU5203199A (en) 1998-05-26 1999-12-13 Procter & Gamble Company, The Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
AU4411699A (en) 1998-06-05 1999-12-20 Human Genome Sciences, Inc. Interferon receptor hkaef92
US7538086B2 (en) 1998-09-01 2009-05-26 Genentech, Inc. PRO1303 polypeptides
JP2002524514A (ja) * 1998-09-17 2002-08-06 イーライ・リリー・アンド・カンパニー タンパク質製剤
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
EP1141008A1 (en) 1998-12-31 2001-10-10 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
ATE478145T1 (de) 1999-06-02 2010-09-15 Genentech Inc Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
US20050060101A1 (en) 1999-06-28 2005-03-17 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
HUP0203133A3 (en) 1999-10-04 2005-07-28 Chiron Corp Emeryville Stabilized liquid polypeptide-containing pharmaceutical compositions
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
AU783473B2 (en) 1999-12-23 2005-10-27 Zymogenetics Inc. Soluble interleukin-20 receptor
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
AU5133601A (en) 2000-04-07 2001-10-23 Ellis L Kline Methods and compositions for treating neoplasms
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
JP5490972B2 (ja) 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
EP2177616B1 (en) 2000-08-08 2012-02-29 ZymoGenetics, Inc. Soluble zcytor 11 cytokine receptors
WO2002013860A1 (fr) 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees contenant un anticorps
EP2116265B1 (en) 2000-10-12 2020-12-23 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2002070001A2 (en) 2001-02-28 2002-09-12 Eli Lilly And Company Use of lp82 to treat hematopoietic disorders
AU2002245652A1 (en) 2001-03-09 2002-09-24 Zymogenetics, Inc. Soluble heterodimeric cytokine receptor
ES2338218T3 (es) * 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
EP1432431B1 (en) 2001-10-04 2017-05-10 Genetics Institute LLC Methods and compositions for modulating interleukin-21 activity
US7022289B1 (en) 2001-10-10 2006-04-04 The United States Of America As Represented By The Secretary Of The Army Chemical and biological sampling device and kit and method of use thereof
PT1562968E (pt) * 2001-11-14 2013-10-23 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
US7582287B2 (en) 2001-12-17 2009-09-01 Zymogenetics, Inc. Method for treating cervical cancer
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
CA2481304A1 (en) 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
US20040009168A1 (en) 2002-04-05 2004-01-15 Elizabet Kaisheva Multidose antibody formulation
WO2005123131A2 (en) 2004-06-14 2005-12-29 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
ATE546150T1 (de) 2002-06-07 2012-03-15 Zymogenetics Inc Verwendung von il-21 und monoklonalem antikörper zur behandlung von fester tumore
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
CA2490423A1 (en) 2002-06-21 2003-12-31 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
ATE338713T1 (de) 2002-07-18 2006-09-15 Perini Fabio Spa Speichereinheit für längliche produkte
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
SI2236154T1 (en) 2003-02-10 2018-08-31 Biogen Ma Inc. THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION
ES2609010T3 (es) * 2003-04-04 2017-04-18 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
PT1648509E (pt) 2003-07-15 2012-10-18 Amgen Inc Anticorpos neutralizantes anti-ngf humanos como inibidores selectivos da via de ngf
PL1698640T5 (pl) 2003-10-01 2019-12-31 Kyowa Hakko Kirin Co., Ltd. Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu
EP1712240B1 (en) 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
DE602005022475D1 (de) 2004-10-22 2010-09-02 Zymogenetics Inc Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
AU2006212807A1 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
US7525604B2 (en) 2005-03-15 2009-04-28 Naxellent, Llc Windows with electrically controllable transmission and reflection
ATE501248T1 (de) 2005-07-02 2011-03-15 Arecor Ltd Stabile wässrige systeme mit proteinen
WO2007006858A2 (en) 2005-07-12 2007-01-18 Oy Jurilab Ltd Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
WO2007037795A2 (en) 2005-08-05 2007-04-05 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
WO2007038501A2 (en) 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers
CA2624359A1 (en) 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
AU2006315026B2 (en) 2005-11-21 2012-11-22 Sanofi Pasteur Limited Stabilizing formulations for recombinant viruses
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
US20080071063A1 (en) 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
JP2009530699A (ja) 2006-03-15 2009-08-27 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ ロール検出を備えたリモートコントロール型ポインティング技術
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
EP2006380A4 (en) 2006-03-23 2010-08-11 Kyowa Hakko Kirin Co Ltd AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR
MX2008012295A (es) * 2006-03-28 2008-10-09 Hoffmann La Roche Formulacion de un anticuerpo monoclonal humano anti-igf-1r.
EP1857559A1 (en) 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
JP2009540015A (ja) 2006-06-14 2009-11-19 イムクローン・リミテッド・ライアビリティ・カンパニー 抗ｅｇｆｒ抗体の凍結乾燥製剤
CA2652924A1 (en) 2006-06-19 2007-12-27 Wyeth Methods of modulating il-22 and il-17
BRPI0712953B8 (pt) 2006-06-30 2021-05-25 Novo Nordisk As anticorpos anti-nkg2a, seu uso, e composição farmacêutica
CA2665567C (en) 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
JP2010506839A (ja) 2006-10-12 2010-03-04 ワイス エルエルシー 乳光の低減を伴う方法および組成物
WO2008048986A2 (en) 2006-10-17 2008-04-24 Children's Hospital Medical Center Gene array technique for predicting response in inflammatory bowel diseases
JP2010508838A (ja) 2006-11-09 2010-03-25 アンスティテュ ナシオナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル（イーエヌエスエーエールエム） ＴＮＦ−α遮断薬に対する治療応答性の予測方法
US20110070225A1 (en) 2006-11-12 2011-03-24 Pierre Goldbach Beta antibody parenteral formulation
BRPI0806313A2 (pt) * 2007-01-09 2011-09-06 Wyeth Corp Formulação de anticorpo anti-il-13; formulação em aerossol de um anticorpo anti-il-13; formulaçãoliofilizada de um anticorpo anti-il-13; composição farmacêutica para o tratamento de um transtorno relacionado a il-13; fabricação de uma composição farmacêutica ; método de tratamento de um transtorno relacionado a il-13; seringa injetável; dispositivo para administração nasal; emplastro transdérmico; bolsa intravenosa; kit compreendendo pelo menos um recipiente; kit; e seringa injetável previamente enchida
EP2132343B1 (en) 2007-03-01 2012-08-29 Université Catholique de Louvain Method for the determination and the classification of rheumatic conditions
CN101601127B (zh) 2007-03-23 2011-02-16 松下电器产业株式会社 导电性凸起及其制造方法以及电子部件安装结构体
US20110130544A1 (en) 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
WO2008132176A2 (en) 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
EP2167687B1 (en) 2007-06-08 2013-03-27 Biogen Idec MA Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US20080311119A1 (en) 2007-06-14 2008-12-18 Biogen Idec Ma Inc. Antibody formulations
US20090004189A1 (en) 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
AU2008269086B2 (en) 2007-06-25 2014-06-12 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2009009406A1 (en) 2007-07-06 2009-01-15 Smithkline Beecham Corporation Antibody formulations
WO2009013538A2 (en) 2007-07-20 2009-01-29 National Institute For Bioprocessing Research And Training Glycosylation markers for cancer and chronic inflammation
US20100261613A1 (en) 2007-07-26 2010-10-14 Michael Centola Methods for inflammatory disease management
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
AU2008337517B2 (en) 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
ES2562627T3 (es) 2008-02-20 2016-03-07 Novo Nordisk A/S Anticuerpos anti-C5aR humanizados
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
CN103396480A (zh) 2008-05-15 2013-11-20 诺沃—诺迪斯克有限公司 抗体纯化方法
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
AU2009265808B2 (en) 2008-06-30 2014-10-23 Novo Nordisk A/S Anti-human interleukin-20 antibodies
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CA2735155A1 (en) 2008-08-28 2010-03-04 Wyeth Llc Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
AU2009294680A1 (en) 2008-09-19 2010-03-25 F. Hoffmann-La Roche Ag Novel antibody formulation
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
EP2746294A3 (en) * 2008-12-22 2015-01-07 Novo Nordisk A/S Antibodies
US20120020954A1 (en) 2009-03-30 2012-01-26 Anat Achiron Methods of predicting clinical course and treating multiple sclerosis
WO2011028945A1 (en) 2009-09-03 2011-03-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
WO2011047073A2 (en) 2009-10-16 2011-04-21 Mayo Foundation For Medical Education And Research Assessing rheumatoid arthritis
US8580528B2 (en) 2009-10-16 2013-11-12 Stichting Vu-Vumc Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
EP2575761B1 (en) * 2010-05-28 2024-08-14 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
JP2013529089A (ja) 2010-06-07 2013-07-18 エフ．ホフマン−ラ ロシュ アーゲー インターロイキン−６受容体を阻害するモノクローナル抗体による薬剤治療に対する応答を予測するための遺伝子発現マーカー
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9795674B2 (en) 2010-02-26 2017-10-24 Novo Nordisk A/S Stable antibody containing compositions
US10709782B2 (en) 2010-02-26 2020-07-14 Novo Nordisk A/S Stable antibody containing compositions
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
US10835602B2 (en) 2010-05-28 2020-11-17 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
US9849181B2 (en) 2012-08-31 2017-12-26 Bayer Healthcare Llc High concentration antibody and protein formulations
WO2021094917A1 (en) * 2019-11-13 2021-05-20 Pfizer Inc. Stable aqueous anti-tfpi antibody formulation

Also Published As

Publication number Publication date
US20180104335A1 (en) 2018-04-19
EP2575761C0 (en) 2024-08-14
RS66182B1 (sr) 2024-12-31
BR112012030139A2 (pt) 2017-06-13
KR20130086144A (ko) 2013-07-31
ES2993022T3 (en) 2024-12-20
JP6239657B2 (ja) 2017-11-29
CN105055306B (zh) 2019-10-01
AU2011257219B2 (en) 2014-12-04
HRP20241526T1 (hr) 2025-01-03
JP2016084367A (ja) 2016-05-19
US10835602B2 (en) 2020-11-17
CN102905692B (zh) 2015-09-16
CA2800188A1 (en) 2011-12-01
JP2018030879A (ja) 2018-03-01
JP6568917B2 (ja) 2019-08-28
EP2575761A1 (en) 2013-04-10
CN102905692A (zh) 2013-01-30
EP2575761B1 (en) 2024-08-14
RU2012153786A (ru) 2014-07-10
CN105055306A (zh) 2015-11-18
WO2011147921A1 (en) 2011-12-01
MX2012013586A (es) 2013-01-24
AU2011257219A1 (en) 2012-11-22
JP6294075B2 (ja) 2018-03-14
JP2013527189A (ja) 2013-06-27

Similar Documents

Publication Publication Date Title
US10835602B2 (en) Stable multi-dose compositions comprising an antibody and a preservative
US10709782B2 (en) Stable antibody containing compositions
US12257343B2 (en) Excipients to reduce the viscosity of antibody formulations and formulation compositions
US20170056504A1 (en) Method of extending half-life of crystaline antibodies
EP3236942A1 (en) Protein compositions and use thereof
US20200147070A1 (en) Inducing phospholipidosis for enhancing therapeutic efficacy
TW202045206A (zh) 抗體調配物

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVO NORDISK A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PARSHAD, HENRIK;ENGELUND, DORTE KOT;SIGNING DATES FROM 20121128 TO 20121129;REEL/FRAME:029650/0215

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION